Use of tamsulosin and dutasteride combination for the management of benign prostatic hyperplasia: a real world practice survey (VELTAM survey)
Keywords:Benign prostatic hyperplasia, Drug drug interaction, Anti-hypertensive effect, Real word practice data
Background: Benign prostatic hyperplasia has high prevalence ranging from 8-80% affecting male population. Dutasteride and tamsulosin combination has been found to be more effective as compared to individual monotherapy. However, evidence on real world clinical experience on this combination is lacking. Aim and Objective of current study was to gather the evidence on real world clinical experience from the physicians using the combination of tamsulosin and dutasteride for the management of BPH.
Methods: Responses from 1571 physicians who were the current prescribers of tamsulosin with dutasteride combination for the management of BPH were collected in a questioner containing a set of nine questions having multiple choice answers. All the data is expressed as number and percentage.
Results: Majority of the physicians considered tamsulosin with dutasteride combination as the gold standard therapy for the treatment of BPH (88.86%). Most common co-morbidities which physician takes in to consideration was cardiovascular (62.61%) followed by asthma (23.04%). While treating BPH patients with cardiovascular co-morbidities, majority of the physician consider drug-drug interaction as significant criteria to decide the therapy (87.83%).
Conclusions: Physicians considered tamsulosin and dutasteride combination as the gold standard for the management of BPH with cardiovascular co-morbidity. Tamsulosin and dutasteride combination is the first line choice for the management of BPH in real world practice.
Alhakamy NA, Fahmy UA, Ahmed QAA. Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation. Pharmaceutics 2019; 11 (640):1-13.
Amano T, Earle C, Imao T, Matsumoto Y, Kishikage T. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male 2018; 21:77–82.
Agrawal M, Kumar M, Pandey S, Aggarwal A, Sankhwar S. Changing profiles of patients undergoing transurethral resection of the prostate over a decade: A single-center experience. Urology Annals 2019;11(3):270-5.
Geitona M, Karabela P, Katsoulis IA. Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting. BMC Urol 2014;14:78.
Gravas S, de la Rosette JJ. Investigational therapies targeted to the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2013;22(3):357-68.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434–41.
Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2007;9(4):181-90
Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57(1):123-31.
Djavan B, Dianat SS, Kazzazi A. Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin. Patient Relat Outcome Meas 2011;2:71-9.
Montorsi F, Henkel T, Geboers A. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010;64:1042-51.
Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31.
McVary KT. BPH: Epidemiology and Comorbidities. Am J Manag Care 2006;12:S122-S12.
Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective a1A-adrenergic antagonist. Urology 1998;51:861-72.
Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoreceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994;113:723-8.
Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant a1-adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-7.
Zaman Huri H, Hui Xin C, Sulaiman CZ. Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study. PLoS One 2014;9(1):e86215.